Breaking News

Clinipace Completes Choice Pharma Merger

By Kristin Brooks | March 11, 2014

Expands global footprint in Asia

Clinipace Worldwide has completed the merger with Choice Pharma, a Pan-Asian CRO, extending its global footprint to include 20 operational offices in 15 countries, including new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia. According to the company, there are no layoffs or office closings planned. Terms of the transaction were not disclosed.

The combined company offers global clinical development services, along with product development, regulatory, and GxP/CMC/QA consultancy. Clinipace and Choice clients now have access to new markets for site activation and patient enrollment. Together, Clinipace will have more than 640 global staff with experience managing more than 1,500 clinical studies and 300 completed regulatory and strategic development engagements.

Chris Wang of Choice Pharma will continue to serve as managing director of Asian operations, reporting to Clinipace chief executive officer, Jeff Williams. “In order to continue to address the changing industry landscape and the high demand by clients for operations in Asia, we began the process of determining the best path for investing in the growth of our company, which led us to Choice Pharma,” said Mr. Williams, Clinipace Worldwide. “With complementary operational strengths, a great reputation for quality and an experienced management team, the decision to combine the two companies was the best solution to continue to meet the long-term strategic goals of clients on both sides.”

“A streamlined, efficient operational approach with real-time transparency that reduces cost and budget volatility is the future of clinical trials,” said Ms. Wang of Choice Pharma. “Not only can our clients leverage Clinipace’s dCRO delivery model, but they now have access to a comprehensive and integrated clinical operations, data management, biostatistics, and regulatory consultancy outside of Asia.”

 

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016